echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The GAS6/AXL inhibitor combination therapy introduced by Sidi Pharmaceuticals was approved for clinical use

    The GAS6/AXL inhibitor combination therapy introduced by Sidi Pharmaceuticals was approved for clinical use

    • Last Update: 2022-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 18, Sidi Medicine announced that its multi-center, open-label Phase 1b/2 clinical trial application for 3D229 injection combined with envolimab injection or lenvatinib in the treatment of advanced solid tumors was approved in China


    Screenshot source: CDE official website

    Studies have shown that the GAS6-AXL signaling pathway is a key pathway that promotes tumor growth and metastasis, tumor immune escape and drug tolerance


    According to the earlier public information of Sidi Medicine, 3D229 (also known as: AVB-500) is the core anti-cancer product of Aravive


    This approval is a Phase 1b/2 clinical study in patients with advanced solid tumors of non-small cell lung cancer, clear renal cell carcinoma and urothelial carcinoma, which aims to evaluate the efficacy of 3D229 injection in combination with Envolitinib alone.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.